Ann: Syd Capital Markets Briefing Presentation, page-85

The fate was that the regulators were never going to let them bring the implant to the consumer market, not without a significant amount of supporting data (which they now almost have with the Vitilgo trial progressing well). The company would've gone to zero trying to if it weren't for Wolgen coming on board and shifting to a clinical focus in order to get the regulators on board. The EPT days are proof of why this conservative and quiet approach is needed, when they have the necessary data and approvals they can become loud and proud but until then, the strategy they're taking makes a lot of sense in my view.